Peer Reviewed Articles

Explore published peer-reviewed articles studying clinical use of the formulation components of QZQ® BOOST, as well as articles referencing the studies:

The articles present peer-reviewed technical/medical/scientific studies strongly supporting the efficacy of the components of QZQ® Boost in supporting and strengthening the immune response against infection. Below, you can explore Summaries of the landmark research articles that QZQ® Boost is based on. More detail is provided in the full-length articles listed after the Summaries. The listing provides links to the landmark research and also to the articles and book chapters of other biomedical researchers positively citing the landmark research results.

We would love to hear from you if you have comments or questions regarding the landmark research
or the remarkable QZQ® BOOST immune enhancing supplement.

Send Message Here


From the Journal of Evidence-Based Integrative Medicine (JEBIM) Presenting landmark 20-Week Study conducted during COVID outbreak, and the remarkable results. The article has been widely cited in science/medicine journals and books.

This study started early in the COVID pandemic. Doctors at a clinic were seeking a natural supplementation protocol to protect clinic patients and staff from sicknesses that were sweeping the nation and the globe, with a focus on COVID, then very poorly understood. Volunteers, all initially without flu or COVID symptoms, agreed to be part of the study, forming a “Test Group” and a “Control Group.” The Test Group (53 people) were those who committed to follow the protocol throughout the 20-week Study period. The Control Group (60 people) were those not following the protocol. As the article reported after the 20-week period, the results were remarkable:

  • Of the Test Group (following the protocol) only two out of 53 developed any flu-like symptoms, and neither of the two proved to have COVID. The flu-like symptoms were mild and cleared quickly.
  • Of the Control Group (not following the protocol, though some had already been taking vitamin C and/or vitamin D, and continued doing so throughout the Study months), 12 developed flu-like symptoms and 9 of those 12 proved to have COVID, their symptoms ranging from mild to severe and of various durations.
The study article has had over 98,000 downloads/views (see also the copy available from the National Center for Biotechnology Information, Numerous people following the study protocol report a boost of immune response in the face of widespread illness.


Study authors’ reply to a letter to the JEBIM editor.

After publication of the 20-Week Study, a letter to the editor of JEBIM claimed that the Study’s results could be accounted for by members of the Study’s two groups having self-selected whether or not to commit to the protocol.

The 20-Week Study authors replied that they had been well aware in structuring the study of possible introduction of such a bias: That the Test Group members were not just more willing to commit to potentially healthy undertakings than the Control Group members but were actually healthier.

The 20-Week Study article had explicitly stated that concern and the study’s analyses had progressively “handicapped” Test Group data relative to Control Group data to compensate. Of relevance also was that the two groups shared approximately equal health profiles (including COVID-comorbidities) going into the study.

The study authors reviewed and explained the study’s data analyses, pointing out that the bias suggested by the letter writer (whose own renowned studies carefully teased out from massive large-data analyses 5-15% health improvement resulting from use of various supplements), could have perhaps contributed to a small fraction of the positive results of the 20-Week Study. But the suggested bias was hardly sufficient to account for the 20-Weeks Study’s approximately 500% better health outcomes of the Test Group over the Control Group.


Study authors' 2020 review of potential treatments & then-interim Study results

When the 20-Week study had gotten underway in early Spring 2020, promising results became apparent at five weeks into the research effort, too early for a significant report, but an appropriate time to alert practitioners / researchers to stay tuned. Also, in early 2020, diabetes was recognized as a serious COVID-comorbidity, accounting then for a notable percentage of deaths. Therefore, the fit of the authors’ early-stage research to the Journal of Diabetes & Treatment was well and widely appreciated by practitioners / researchers, with hundreds of new downloads / reads of the article continuing across the globe even now.

Besides presenting the study-protocol formulation and the early-stage results, the article described additional therapeutic approaches being explored by the authors, including auxiliary supplementation, breathing / relaxation exercises, heat therapy and site UV-sterilization. Additionally, the article presented a live-link survey of dozens of approaches then currently being pursued within the global scientific community to combat COVID.


  • Peer Reviewed Study

    Read Article 

    Study authors' reply to a letter to the JEBIM editor
    Read Reply

    Study authors' 2020 review of potential treatments & then-interim Study results
    Read Article

  • Peer Reviewed Articles Citing JEBIM Study/Pending Patent:

    Read Article

    Read Article

    LIFE 2022, 12, 6
    Read Article

    ANTIOXIDANTS 2022, 11, 876
    Read Article

  • Articles / Book Chapters / News / Commentary Citing JEBIM Study:

    Read Article

    Quinone and SARS-CoV-2
    (Ch. 3 of "Application of Natural Products in SARS-CoV-2" (January 2023))
    See Chapter Abstract

    GLOBAL PUBLIC HEALTH February 15, 2022
    Read Article

    REVYUH April 12, 2022
    Read Article



The recent article below published in Lancet emphasizes the importance of immune boosting – almost half (45 % ) of hospitalized COVID patients had long term problems that had a serious impact on their health ...